Find, compare & contact
Bimekizumab API Manufacturers & Suppliers

General Description:

Bimekizumab, identified by CAS number 1418205-77-2, is a notable compound with significant therapeutic applications. Bimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. It is the first IL-17 inhibitor to target both IL-17A and IL-17F. It has demonstrated superior efficacy as compared to another IL-17 inhibitor, , as well as (an IL-12/23 inhibitor) and (a TNF inhibitor) in the treatment of moderate-to-severe psoriasis, likely owing to its dual inhibition of both IL-17A and IL-17F.

Indications:

This drug is primarily indicated for: Bimekizumab is indicated in the EU for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Bimekizumab undergoes metabolic processing primarily in: As a monoclonal antibody, bimekizumab is likely degraded into smaller peptides and amino acids via catabolic processes. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Bimekizumab are crucial for its therapeutic efficacy: In healthy volunteers, the absolute bioavailability of bimekizumab following subcutaneous injection was 70.1%. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Bimekizumab is an important consideration for its dosing schedule: The mean terminal elimination half-life of bimekizumab in patients with plaque psoriasis was 23 days. This determines the duration of action and helps in formulating effective dosing regimens.

Volume of Distribution:

Bimekizumab is distributed throughout the body with a volume of distribution of: In patients with plaque psoriasis, the median volume of distribution at steady-state was 11.2 L. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Bimekizumab is a critical factor in determining its safe and effective dosage: The median apparent clearance of bimekuzmab in patients with plaque psoriasis was 0.337 L/day. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Bimekizumab exerts its therapeutic effects through: Bimekizumab exerts its pharmacologic effects by binding to and inhibiting one of the pro-inflammatory cytokines involved in psoriasis pathogenesis. It is administered once-monthly as a subcutaneous injection. Bimekizumab may increased the risk of infection, including upper respiratory tract infections and oral candidiasis. Any clinically important active infections should be resolved prior to therapy. In addition, the use of live vaccines during bimekizumab therapy is not recommended - ensure patients beginning therapy have completed all age appropriate immunizations prior to initiation. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Bimekizumab functions by: The pathophysiology of psoriasis involves a dysregulation of the immune system and is facilitated by a variety of cytokines released by dendritic cells and T-helper cells. Plaque psoriasis, the most common subtype of psoriasis, is driven primarily by tumor necrosis factor-alpha (TNF-α) and interleukins 17 and 23 (IL-17 and IL-23), with the axis between these three cytokines integral to the maintenance phase of psoriasis. IL-17 acts through two separate mechanisms: the first, dependent on the cytoplasmic adaptor protein ACT1, involves the activation of NF-κB and the transcription of inflammatory genes. The second, independent of ACT1, involves the activation of the JAK/STAT signaling cascade, which leads to further transcription of pro-inflammatory proteins and continued psoriasis pathogenicity. Bimekizumab is a monoclonal antibody targeted against IL-17A, IL-17F, and a heterodimer of the two called IL-17AF. It blocks the interaction of these interleukins with their respective receptors, thus reducing psoriatic inflammation. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Bimekizumab belongs to the None, classified under the direct parent group Peptides. This compound is a part of the Organic Compounds, falling under the Organic Acids superclass, and categorized within the Carboxylic Acids and Derivatives class, specifically within the Amino Acids, Peptides, and Analogues subclass.

Categories:

Bimekizumab is categorized under the following therapeutic classes: Agents reducing cytokine levels, Amino Acids, Peptides, and Proteins, Antibodies, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic and Immunomodulating Agents, Blood Proteins, Globulins, Immunoglobulins, Immunoproteins, Immunosuppressive Agents, Interleukin Inhibitors, Proteins, Serum Globulins. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Bimekizumab include:

• Molecular Formula: C6552H10132N1750O2029S42